|
Ferroportin and hepcidin: a new hope in diagnosis, prognosis, and therapy for breast cancer.
Breast Cancer Res. 2010 Oct 6;12(5):314
Authors: Pogribny IP
Abstract
ABSTRACT: Breast cancer is the most prevalent malignancy in women. The success of breast cancer treatment relies on the ability to detect the disease and correct molecular abnormalities at an early stage of disease development. A recent article describes a marked decrease in the levels of ferroportin in breast cancer. More importantly, the presented results demonstrate convincingly the incredible diagnostic and prognostic value of ferroportin and hepcidin gene expression in breast cancer and suggest that determination of these two molecular markers may be used as guidance toward individualized therapy for breast cancer patients.
PMID: 21062518 [PubMed - as supplied by publisher] Read more |
